CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
HXTC infusionbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02208167
NCT02208167Phase 1Completed
CompareCT.gov

IGHID 1320 - A Phase I Study to Evaluate the Safety, Immunologic, and Virologic Responses of HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) as a Therapeutic Strategy in HIV-Infected Individuals Started on Antiretroviral Therapy During Acute and Chronic Infection

University of North Carolina, Chapel Hill·interventional·Posted Aug 4, 2014·Updated Oct 7, 2019

In Brief

A Phase 1 clinical trial evaluating HXTC infusion for HIV. Completed, enrolled 6 participants across 1 site.

Detailed Summary

This is a phase 1, single-site study is to evaluate the safety and immunologic and virologic efficacy of ex vivo expanded HIV-1 multi-antigen specific T-cell (HXTC) therapy in HIV-infected individuals with viral suppression on antiretroviral therapy (ART).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV
CountriesUnited States
CollaboratorsCARE Collaboratory of AIDS Researchers for Eradication, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 4, 2014
Enrollment StartApr 7, 2015
Primary CompletionJan 19, 2017
Study CompletionNov 27, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.9 years ago

Interventions

HXTC infusionbiological